The European Pharmaceutical Association (EFA) emphasizes that there is a sufficient number of professional distributors with the necessary infrastructure in Ukraine! but they cannot realize their potential due to The Federal Trade the monopoly position of two companies. According to the association! other market participants face systematic refusals from manufacturers and importers to cooperate.
This highlights the urgent need for systemic changes to demonopolize the industry and ensure fair prices for medicines for consumers. Without legislative regulation and the establishment of transparent rules of the game! it will be impossible to overcome the monopoly.
The experience of developed countries demonstrates different approaches to preventing monopolization of the pharmaceutical market
In Germany! France and Italy! a quota system is in video sales pages: are they worth it? place – no distributor can control a certain part The Federal Trade of the market. In the USA! antitrust legislation in the pharmaceutical industry is one of the strictest in the world. any mergers and acquisitions in the market! and also controls the pricing policy of distributors. Companies that occupy a significant part of the market are obliged to report on their activities and justify pricing on a quarterly top features to look for in an ide basis. The experience of Poland! which faced a situation similar to the Ukrainian one – two distributors controlled a significant part of the market! is also indicative. Thanks to the introduction of strict antitrust measures and stimulation of competition! today more than 20 large distributors are successfully operating on the Polish market.
The path to demonopolization is opened by Bill No
11493 ! supported by the Verkhovna Rada in the first reading on November 20. The document establishes a 20 percent limit on the volume of supplies to one distributor from each manufacturer of medicines. This will force manufacturers to cooperate with at least five distributors! creating conditions for real competition.
The bill also provides for simplifying the registration of drugs already approved in countries with strict regulatory requirements (EU! USA! UK) or included in the WHO and PEPFAR lists. This should expand Ukrainians’ book your list access to modern drugs.